Added to YB: 2026-04-22
Pitch date: 2026-04-17
GSK [neutral]
GSK plc
-2.94%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 85.6B
Pitch Price
GBP 21.45
Price Target
N/A
Dividend
3.36%
EV/EBITDA
8.63
P/E
15.45
EV/Sales
3.05
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 17/4/2026 - GSK – Pipeline progress
GSK (update): Mo-Rez oncology treatment entering 5 simultaneous phase III trials in 2026, showing strong response rates in ovarian & endometrial cancer w/ promising efficacy/safety. R&D capabilities strengthening, broadening addressable market. Cheap at 10.9x 2027 EPS, 3.5% yield.
Read full article (1 min)